Our findings are consistent with a prior study in Goto-Kakizaki rats with type-2 diabetes demonstrating that the intraocular administration of spironolactone reduced retinal vascular leakage and oedema, although retinal VEGF levels were not reduced [29]. Here, VEGFA is linked to type 2 diabetes mellitus.